A human monoclonal antibody blocking SARS-CoV-2 infection

By Chunyan Wang, Wentao Li, D. Drabek, Nisreen M. A. Okba, R. van Haperen, A. Osterhaus, F. V. van Kuppeveld, B. Haagmans, Frank G. Grosveld, B. Bosch. 2020

1,070 citations recorded by the source corpus.

The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19. Vaccines and targeted therapeutics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are currently lacking. Here, the authors report a human monoclonal antibody capable of neutralizing both authentic SARS-CoV and SARS-CoV-2 by targeting a common epitope.

Subfields: Animal Science and Zoology, Infectious Diseases, Molecular Biology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. S. Gandhi
2. Charles Swanton
3. E. Rosser

Citations in the corpus

• mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (2021, neutral): “Limitations of the study Although previous studies that used pseudovirus neutralization tomodel the sensitivity of replicating SARS-CoV-2 to neutralizing antibodies have shown excellent correlations (Crawford et al., 2020; Ju et al., 2020;Moore et al., 2004; Pinto et al., 2020; Riepler et al., 2020;”
• Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies (2020, neutral): “However, structures of S trimer, RBD-Fab, RBD-ACE2, and S trimer-Fab complexes for SARS-CoV-2 and other coronaviruses are informative for interpreting and understanding the antibody response to SARS-CoV-2 (Gui et al., 2017; Kirchdoerfer et al., 2020; Kirchdoerfer et al., 2016; Kirchdoerfer et al., 2”
• Preexisting and de novo humoral immunity to SARS-CoV-2 in humans (2020, background): “Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. JAMA Pediatr (2020). 49 Grant, P. R., Turner, M. A., Shin, G. Y., Nastouli, E. & Levett, L. J. Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for n”
• Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. (2020, neutral): “8) Specific agents Antivirals (oseltamivir): 38 (99); antibacterials: 41 (100); corticosteroids: 9 (22) Antivirals (oseltamivir, ganciclovir, or lopinavir/ ritonavir): 75 (76); antibacterials: 70 (71); antifungals: 15 (15); corticosteroids: 19 (19); IVIG: 27 (27) Antivirals (oseltamivir): 124 (90); ”
• Stock Market Response during COVID-19 Lockdown Period in India: An Event Study (2020, background): “The outbreak of coronavirus has caused a pandemic of the respiratory disease (COVID-19) for which vaccines and targeted therapeutics for treatment are unavailable (Wang et al. 2020).”